Authors’ Disclosures
P.
ONCOLOGY, EMD
M.A. Carducci reports personal fees from Pfizer, Sanofi Genzyme, and AstraZeneca outside the submitted work. C. Habermehl reports personal fees from Merck KGaA outside the submitted work. F. Rohdich reports other. O. Karpenko reports personal fees from Merck healthcare KGaA, during the conduct of the study; personal fees from Sanofi, AstraZeneca, Daiichi Sankyo, and Sierra Oncology outside the submitted work. C. Gimmi reports a patent to P20-114-IN-PCT pending; and C. Gimmi was an employee of Merck KgAa at the time of the study conduct. P. LoRusso reports other from AbbVie, Agios, Five Prime, GenMab, Halozyme, Roche-Genentech, Genentech, CytomX, Takeda, SOTIO, Cybrexa, Agenus, Tyme, IQVIA, TRIGR, Pfizer, ImmunoMet, Black Diamond, Glaxo-Smith Kline, QED Therapeutics, AstraZeneca, EMD Serono, Shattuck, Astellas, Salarius, MacroGenics, Kyowa Kirin, Kineta, Zentalis, Molecular Templates, ABL Bio, SK Life Sciences, STCube, Bayer, I-Mab, Seagen, imCheck, Relay Therapeutics, Stemline, Compass BADX, Mekanist, Mersana, BAKX Therapeutics, Scenic Biotech, Qualigen, Roivant, Neurotrials, and Actuate Therapeutics outside the submitted work. F. Rohdich and L. Pudelko are employees of the healthcare business of Merck KGaA, Darmstadt, Germany. No disclosures were reported by the other authors.